LMWH Treatment in Patients with Cancer Diagnosed with Venous Thromboembolism

Ali Cemal Düzgün, Ekin İlkeli, Zeynep Uluşan

Venous thromboembolism (VTE) is associated with increased mortality and morbidity in cancer patients, and VTE development is among the most frequent causes of death in cancer patients. In this study, we evaluated the efficacy of enoxaparin and tinzaparin on thrombosis development in 36 cancer patients. Of 36 the cases, 14 were given enoxaparin (single dose, 6000 anti-Xa/0.6 ml, s.c.), and 22 were given tinzaparin (single dose 20.000 IU/0.7 ml, s.c.). The improvement was observed following the treatment in Doppler ultrasonography and the resolution of VTE was clinically detectable. We did not observe any signs of a new thrombus development or bleeding in the patient group. We detected a longer survival time in patients with enoxaparin treatment (p<0.05). We conclude that low-molecular-weight heparins are an efficient treatment method for VTE in cancer patients.

Keywords: LMWH, cancer, venous thromboembolism, enoxaparin, tinzaparin https://doi.org/10.36864/jinasvs.2021.1.008